- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04495088
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group
Study Overview
Status
Conditions
Detailed Description
Patients with locally advanced rectal cancer are generally treated with preoperative 5-FU- or capecitabine-based chemo-radiotherapy (CRT) and total mesorectal excision (TME) surgery in order to decrease the rate of local failure. In patients with low risk for local failure in the middle third of the rectum (cT3a/b, N-) as determined with quality controlled MRI, the German S3 guidelines and the ESMO clinical practice guidelines state that neoadjuvant radiotherapy may be omitted. However, distant failure rate is still substantial in the range of 20-25% in these patients highlighting the need for more effective systemic treatment.
The hereby proposed ACO/ARO/AIO-18.2 randomized trial incorporates three novel aspects: (1) patient selection relies on strict and quality controlled MRI features and therefore identifies a cohort without imminent need for radiotherapy, (2) the sequence of chemotherapy and surgery is changed in a way that chemotherapy is administered preoperatively to increase the rate of patients treated with chemotherapy, and (3) three months of neoadjuvant FOLFOX or XELOX (instead of up to 6 months adjuvant chemotherapy) are used as a sole perioperative treatment in order to administer effective doses of the presumably most effective perioperative treatment at an early time point during the course of disease.
Thus, patients with locally advanced rectal cancer but low risk for local failure (cT1/2N+ in all thirds of the rectum, cT3a/b N- in the middle third, and cT3-4 Nany in the upper third) will be included and randomized between three months of neoadjuvant FOLFOX/XELOX in Arm A and primary resection of the tumor followed by risk (i.e. stage) adapted chemotherapy in Arm B.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Ralf-Dieter Hofheinz, Prof. Dr.
- Phone Number: 2855 +49 621 383
- Email: ralf.hofheinz@umm.de
Study Contact Backup
- Name: Benedict Atzler
- Phone Number: 7052 +49 69 7601
- Email: atzler.benedict@ikf-khnw.de
Study Locations
-
-
-
Mannheim, Germany, 68167
- Recruiting
- Unversity Hospital Mannheim
-
Contact:
- Ralf Hofheinz, Prof.
- Phone Number: +49 621 383 2855
- Email: Ralf.Hofheinz@umm.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female patients with histologically confirmed diagnosis of rectal adenocarcinoma localised 0 - 16 cm from the anocutaneous line as measured by rigid rectoscopy (i.e. lower, middle and upper third of the rectum), depending on MRI-defined inclusion criteria (see below).
- Staging requirements: High-resolution magnetic resonance imaging (MRI) of the pelvis is the mandatory local staging procedure.
- Transrectal endoscopic ultrasound (EUS) is used to help discriminate between T1/2 and early T3 tumors.
MRI-defined inclusion criteria:
- Lower third (0-6 cm): cT1/2 with clear cN+ based on MRI-criteria (see SOP in chapter 13.3 of the appendix), provided CRM- and EMVI- (defined as MRI-EMVI score 0-3; see SOP in chapter 13.3 of the appendix)
- Middle third (≥ 6-12 cm): cT1/2 with clear cN+ provided CRM- and EMVI-; cT3a/b, i.e. evidence of extramural tumor spread into the mesorectal fat of ≤ 5 mm provided N-, CRM-, and EMVI-
- Upper third (≥ 12-16 cm): cT1/2 with clear cN+ provided CRM- and EMVI-; any cT3-4 irrespective of nodal status.
- Spiral-CT of the abdomen and chest to exclude distant metastases.
- Aged at least 18 years. No upper age limit.
- WHO/ECOG Performance Status ≤1.
- Adequate haematological, hepatic, renal and metabolic function parameters:
- Leukocytes ≥ 3.000/mm³, ANC ≥ 2.000/mm³, platelets ≥ 100.000/mm³, Hb > 9 g/dl
- Serum creatinine ≤ 1.5 x upper limit of normal
- Bilirubin ≤ 2.0 mg/dl, SGOT-SGPT, and AP ≤ 3 x upper limit of normal.
- QTc interval (Bazett**) ≤ 440 ms
- Informed consent of the patient.
"**" Formula for QTc interval calculation (Bazett): QTc= ((QT) ̅" (ms)" )/√(RR (sec))= ((QT) ̅" (ms)" )/√(60/(frequency (1/min)))
Exclusion Criteria:
- Distant metastases (to be excluded by CT scan of the thorax and abdomen).
- Prior antineoplastic therapy for rectal cancer.
- Prior radiotherapy of the pelvic region.
- Major surgery within the last 4 weeks prior to inclusion.
- Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
- Subject (male or female) is not willing to use highly effective*** methods of contraception during treatment and for 6 months (male or female) after the end of treatment Male patients treated with Oxaliplatin should take legal advice concerning sperm conservation before start of therapy and should additionally use a condom during treatment period. Their female partner of childbearing potential should also use an appropriate contraceptive measure.
- On-treatment participation in a clinical study in the period 30 days prior to inclusion.
- Previous or current drug abuse.
- Other concomitant antineoplastic therapy.
- Serious concurrent diseases, including neurologic or psychiatric disorders (incl. dementia and uncontrolled seizures), active, uncontrolled infections, active, disseminated coagulation disorder.
- Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 6 months before enrolment.
- Chronic diarrhea (> grade 1 according NCI CTCAE).
- Prior or concurrent malignancy ≤ 3 years prior to enrolment in study (Exception: non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1), if the patient is continuously disease-free.
- Known allergic reactions or hypersensitivity on study medication or to any of the other excipients.
- Evidence of peripheral sensory neuropathy > grade 1 according to CTCAE version 5.0 (see appendix).
- Severe kidney dysfunction (creatinine clearance < 30 ml/min).
- Recent or concurrent treatment with brivudine.
- Pernicious or other megaloblastic anaemia caused by vitamin B12 deficiency.
- Known dihydropyrimidine dehydrogenase deficiency.
- Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (these conditions should be discussed with the patient before registration in the trial).
"***"highly effective (i.e. failure rate of <1% per year when used consistently and correctly) methods: intravaginal and transdermal combined (estrogen and progestogen containing) hormonal contraception; injectable and implantable progestogen-only hormonal contraception; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; sexual abstinence (complete abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A (experimental arm)
The experimental arm A starts with 6 cycles of mFOLFOX or 4 cycles of XELOX.
Surgery is scheduled four or six weeks after day 1 of the last mFOLFOX or XELOX cycle, respectively.
No postoperative chemotherapy is planned
|
neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1.
Cycles are repeated on day 15.
A total of 6 cycles are administered.
Other Names:
neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v.
day 1 Cycles are repeated on day 22.
A total of 4 cycles are administered.
Other Names:
|
Active Comparator: B (control arm)
In the standard arm B, patients undergo surgical resection of the primary tumor followed by stage- (risk-)adapted adjuvant chemotherapy 4-8 weeks after surgery according to recommendations of the S3 guidelines in analogy to colon cancer.
Details of the recommended protocols are provided in the protocol.
|
adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1.
Cycles are repeated on day 15.
A total of 6 cycles are administered.
Other Names:
adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v.
day 1 Cycles are repeated on day 22.
A total of 4 cycles are administered.
Other Names:
adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22.
A total of 8 cycles are administered.
Other Names:
adjuvant application Folinic acid 2h i.v.
500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
Other Names:
adjuvant application Folinic acid 2h i.v.
200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
disease-free survival
Time Frame: up to 3 years
|
time from randomisation to one of the following events: no surgery or non-radical (R2) surgery of the primary tumour, locoregional recurrence after R0/1 resection of the primary tumour, second primary colorectal or other cancer, metastatic disease or progression, or death from any cause, whichever occurred first.
|
up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute and late toxicity
Time Frame: From date of informed consent until the End of Treatment or 30 days after the last dose of study treatment
|
assessment of acute and late toxicity according to NCI CTCAE version 5.0
|
From date of informed consent until the End of Treatment or 30 days after the last dose of study treatment
|
Compliance (completion rate) of chemotherapy
Time Frame: From date of randomization until end of chemotherapy, approx. 12 (arm A) respectively up to 34 (arm B) weeks after randomization
|
Rate of completion of administered chemotherapy
|
From date of randomization until end of chemotherapy, approx. 12 (arm A) respectively up to 34 (arm B) weeks after randomization
|
Surgical morbidity and complications
Time Frame: After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization
|
Surgical morbidity and complications if surgery is performed and events occur
|
After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization
|
Pathological UICC-staging, including pCR (ypT0N0) rate
Time Frame: After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization
|
Pathological staging according UICC criteria, including detailed information about pathologically assessed complete response rate (ypT0N0)
|
After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization
|
R0 resection rate, Negative circumferential resection rate (CRM > 1mm)
Time Frame: After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization
|
defined as microscopically margin negative resection with no gross or microscopic tumor remains in the area of the primary tumor and/or samples regional lymph nodes based on evaluation by the local pathologist
|
After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization
|
Tumor regression grading according to Dworak in the experimental arm
Time Frame: After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization
|
Grading of tumor regression according to Dworak in the experimental arm
|
After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization
|
Rate of sphincter-sparing surgery
Time Frame: After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization
|
Rate of sphincter-sparing surgery if surgery is performed
|
After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization
|
Rate of W&W with or without local regrowth
Time Frame: Up to 5 years after end of treatment
|
Number of performed watch&wait approaches with or without local regrowth compared to planned and performed surgery
|
Up to 5 years after end of treatment
|
Cumulative incidence of local and distant recurrences
Time Frame: Up to 5 years after end of treatment
|
Total number of local and distant recurrences, if they occur
|
Up to 5 years after end of treatment
|
Overall survival
Time Frame: Up to at least 3 years and until 5 years
|
Overall survival is defined as the time interval between the date of randomization and the date of death of any cause.
Patients who are still alive when last traced will be censored at the date of last follow-up
|
Up to at least 3 years and until 5 years
|
Patient reported outcome: Quality of life according to questionnaire EORTC-QLQ-C30
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever occured first, assessed up to approximately 68 months
|
Quality of life scores according to validated questionnaires EORTC-QLQ-C30, based on treatment arm, and surgical procedures.
30 questions; score values from 1 (not at all) to 4 (very much) respectively from 1 (very poor) to 7 (excellent).
Score outcome depends on score type.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever occured first, assessed up to approximately 68 months
|
Patient reported outcome: Quality of life according to questionnaire EORTC-QLQ-CR29
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever occured first, assessed up to approximately 68 months
|
Quality of life scores according to validated questionnaires EORTC-QLQ-CR29, based on treatment arm, and surgical procedures.
29 questions; score values from 1 (not at all) to 4 (very much).
Score outcome depends on score type.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever occured first, assessed up to approximately 68 months
|
Patient reported outcome: Functional outcome according to Wexner score
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever occured first, assessed up to approximately 68 months
|
Functional score according to validated Wexner score, based on treatment arm, and surgical procedures.
5 questions; five score values from "never" to "1 per day or more often".
The more often the worse the outcome.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever occured first, assessed up to approximately 68 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ralf-Dieter Hofheinz, Prof. Dr., Universitätsmedizin Mannheim
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Hematinics
- Fluorouracil
- Capecitabine
- Oxaliplatin
- Leucovorin
- Levoleucovorin
- Folic Acid
Other Study ID Numbers
- ACO/ARO/AIO-18.2
- 2018-001356-35 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
Clinical Trials on mFOLFOX (neoadjuvant)
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruitingRadiotherapy | Rectal Neoplasms MalignantChina
-
University of Kansas Medical CenterMerck Sharp & Dohme LLCActive, not recruitingAdenocarcinoma | Stomach Cancer | Gastro Esophageal Junction CancerUnited States
-
University of Texas Southwestern Medical CenterApexigen America, Inc.Active, not recruitingLocally Advanced Rectal AdenocarcinomaUnited States
-
Arcus Biosciences, Inc.CompletedColorectal Cancer | GastroEsophageal CancerUnited States, Australia
-
Yonsei UniversityCompletedHER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract CancerKorea, Republic of
-
Dartmouth-Hitchcock Medical CenterCompletedGastric Cancer | Colorectal Cancer | Esophageal Cancer | Small Bowel Cancer | Appendix Cancer | Ampullary CancerUnited States
-
Cancer Institute and Hospital, Chinese Academy...Xijing Hospital; Peking Union Medical College Hospital; Peking University Cancer... and other collaboratorsActive, not recruiting
-
Chungnam National University HospitalBoryung Pharmaceutical Co., LtdEnrolling by invitation
-
Peking UniversityFudan University; Capital Medical UniversityUnknownStomach Neoplasms | Gastric CancerChina
-
Jiangsu Cancer Institute & HospitalRecruitingLocally Advanced Esophageal CarcinomaChina